KR100504966B1 - 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물 - Google Patents
진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물 Download PDFInfo
- Publication number
- KR100504966B1 KR100504966B1 KR10-2003-0008114A KR20030008114A KR100504966B1 KR 100504966 B1 KR100504966 B1 KR 100504966B1 KR 20030008114 A KR20030008114 A KR 20030008114A KR 100504966 B1 KR100504966 B1 KR 100504966B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginsenoside
- antihypertensive
- blood pressure
- composition
- present
- Prior art date
Links
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 24
- 241000208340 Araliaceae Species 0.000 title description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 title description 12
- 235000008434 ginseng Nutrition 0.000 title description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 title description 2
- 229930182490 saponin Natural products 0.000 title description 2
- 150000007949 saponins Chemical class 0.000 title description 2
- 239000000470 constituent Substances 0.000 title 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 claims abstract description 71
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 claims abstract description 40
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims abstract description 40
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 40
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000002775 capsule Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 18
- 229930182494 ginsenoside Natural products 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000002789 Panax ginseng Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 229940030600 antihypertensive agent Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000004531 blood pressure lowering effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000012711 vitamin K3 Nutrition 0.000 description 3
- 239000011652 vitamin K3 Substances 0.000 description 3
- 229940041603 vitamin k 3 Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 2
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
나이(주) | 9.4 | 11.6 | 13 | 15 | 17 | |
BPs | 180.7±6.3 | 203.0±5.0 | 210.4±4.6 | 212.8±1.5 | 214.6±2.2 | |
BPm | 130.0±8.8 | 164.8±5.2 | 168.2±4.6 | 172.7±1.8 | 169.4±3.3 | |
BPd | 104.6±11.0 | 145.8±5.7 | 146.9±5.2 | 152.7±2.1 | 146.8±3.9 |
처치(주) | 2 | 4 | ||||
군 | BPs | BPm | BPd | BPs | BPm | BPd |
대조군 | 100 | 100 | 100 | 100 | 100 | 100 |
Rg3 | 94.8±2.1* | 93.8±2.2* | 90.8±2.3* | 94.8±2.3* | 93.8±3.1* | 90.8±2.5* |
Rh2 | 99.8±4.3 | 98.8±3.5 | 97.8±2.3 | 98.8±4.1 | 97.8±2.3 | 97.1±3.3 |
Rg3:Rh2=1:1 | 93.7±3.4* | 92.8±3.4* | 86.8±2.3* | 92.8±3.3* | 90.8±2.3* | 89.8±3.1* |
Rg3:Rh2=2.5:1 | 92.8±2.3* | 88.4±2.5* | 85.2±2.4* | 89.9±2.5* | 86.3±3.7* | 85.1±3.8* |
Rg3:Rh2=5:1 | 92.6±3.3* | 90.8±2.3* | 88.8±2.3* | 90.8±2.1* | 89.6±2.3* | 88.8±2.3* |
Rg3:Rh2=10:1 | 94.8±4.3 | 93.7±3.5 | 93.6±2.3 | 94.2±4.1 | 93.3±2.3 | 93.1±3.3 |
Rg3:Rh2=15:1 | 96.8±3.3 | 97.8±4.5 | 97.8±2.3 | 96.8±2.1 | 97.8±3.3 | 96.1±4.3 |
Rg3:Rh2=30:1 | 98.8±2.3 | 98.8±3.5 | 98.8±4.3 | 98.8±4.1 | 98.8±4.3 | 98.1±2.1 |
처치(주) | 4 | ||
군 | BPs | BPm | BPd |
대조군 | 100 | 100 | 100 |
Rg3 | 99.3±10.5 | 98.6±9.5 | 98.4±10.3 |
Rh2 | 100±9.5 | 102±10.1 | 104±10.5 |
Rg3:Rh2=1:1 | 90.0±7.9* | 89.2±6.4* | 88.6±7.5* |
Rg3:Rh2=2.5:1 | 89.4±8.5* | 88.1±6.3* | 88.9±7.2* |
Rg3:Rh2=5:1 | 90.1±6.5* | 88.5±7.6* | 89.7±6.5* |
Rg3:Rh2=10:1 | 100±9.5 | 101±10.1 | 101±10.5 |
Rg3:Rh2=15:1 | 101±9.3 | 102±7.1 | 102±6.5 |
Rg3:Rh2=30:1 | 101±9.7 | 102±6.1 | 102±5.5 |
시간(분) | 0 | 30 | 60 | 90 | 120 |
음성대조군 | 0.0 | 0.7 | 1.2 | 1.5 | 1.7 |
메나디온투여군 | 0.0 | 1.8 | 22.2 | 63.2 | 66.3 |
Rg3 투여군 | 0.0 | 0.5 | 1.3 | 1.7 | 1.9 |
Rh2 투여군 | 0.0 | 0.4 | 1.5 | 1.7 | 1.9 |
Rg3:Rh2=1:1 | 0.0 | 0.8 | 1.4 | 1.6 | 1.5 |
Rg3:Rh2=2.5:1 | 0.0 | 0.5 | 1.2 | 1.5 | 1.6 |
Rg3:Rh2=5:1 | 0.0 | 0.7 | 1.1 | 1.3 | 1.8 |
Rg3:Rh2=10:1 | 0.0 | 0.4 | 1.5 | 1.5 | 1.9 |
Rg3:Rh2=15:1 | 0.0 | 0.4 | 1.5 | 1.7 | 1.5 |
Rg3:Rh2=30:1 | 0.0 | 0.4 | 1.5 | 1.4 | 1.8 |
투여약물 | 시험동물 | 시험농도(mg/kg) | 투 여동물수 | 사 망동물수 | 치사율(%) | LD50 |
Rg3:Rh2=1:1 | 랫트 | 01883757501,5003,000 | 101010101010 | 000000 | 000000 | >3g/kg |
마우스 | 01883757501,5003,000 | 101010101010 | 000000 | 000000 | >3g/kg | |
Rg3:Rh2=5:1 | 랫트 | 01883757501,5003,000 | 101010101010 | 000000 | 000000 | >3g/kg |
마우스 | 01883757501,5003,000 | 101010101010 | 000000 | 000000 | >3g/kg |
Claims (7)
- 진세노사이드 Rg3 및 진세노사이드 Rh2가 5 : 1 내지 2.5 : 1로 함유됨을 특징으로 하는 항고혈압 조성물.
- 제1항에 있어서, 1종 또는 2종 이상의 약제학적으로 허용 가능한 담체 및 첨가제를 함유함을 특징으로 하는 항고혈압 조성물.
- 제2항에 있어서, 담체는 희석제, 활택제, 결합제, 붕해제, 감미제, 안정제, 방부제 중에서 1종 또는 2종 이상 선택됨을 특징으로 하는 항고혈압 조성물.
- 제2항에 있어서, 첨가제는 향료, 비타민 B군중에서 1종 또는 2종 이상 선택됨을 특징으로 하는 항고혈압 조성물.
- 제1항에 있어서, 진세노사이드 Rg3 및 진세노사이드 Rh2의 합계량으로 1일 경구 복용량이 1mg 내지 10mg임을 특징으로 하는 항고혈압 조성물.
- 제2항에 있어서, 제형은 드링크제, 정제, 환제, 캡슐제 또는 주사제 중에서 선택됨을 특징으로 하는 항고혈압 조성물.
- 제6항에 있어서, 진세노사이드 Rg3 및 진세노사이드 Rh2의 합계량으로 각 제형당 1mg 내지 10mg 함유됨을 특징으로 하는 항고혈압 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0008114A KR100504966B1 (ko) | 2003-02-10 | 2003-02-10 | 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0008114A KR100504966B1 (ko) | 2003-02-10 | 2003-02-10 | 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040072153A KR20040072153A (ko) | 2004-08-18 |
KR100504966B1 true KR100504966B1 (ko) | 2005-08-01 |
Family
ID=37359751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0008114A KR100504966B1 (ko) | 2003-02-10 | 2003-02-10 | 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100504966B1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101602910B1 (ko) * | 2011-06-07 | 2016-03-15 | 주식회사 아리바이오 | 진세노사이드의 강화방법 |
KR101222845B1 (ko) * | 2012-03-09 | 2013-01-25 | 주식회사 천지양 | 홍삼 추출물의 감식초 반응 혼합물을 함유한 혈관 질환의 예방 또는 치료용 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR970000239A (ko) * | 1995-06-07 | 1997-01-21 | 박만기 | 약효가 증강된 가공인삼 제품 |
KR100201585B1 (ko) * | 1995-11-22 | 1999-06-15 | 손경식 | 혈관이완제 조성물 |
-
2003
- 2003-02-10 KR KR10-2003-0008114A patent/KR100504966B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR970000239A (ko) * | 1995-06-07 | 1997-01-21 | 박만기 | 약효가 증강된 가공인삼 제품 |
KR100201585B1 (ko) * | 1995-11-22 | 1999-06-15 | 손경식 | 혈관이완제 조성물 |
Non-Patent Citations (2)
Title |
---|
Wang Yu Kim, Jong Moon Kim et al; J. Nat. Prod.; 2000; 63; p1702~1704 * |
Yun TK, Lee YS, Lee YH, Kim SI, Yun HY.; J Korean Med Sci. 2001 Dec;16 Suppl:S6-18 * |
Also Published As
Publication number | Publication date |
---|---|
KR20040072153A (ko) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2531864A1 (fr) | Adminiculum pour agents anti-tumeur comprenant un extrait d'un produit pharmaceutique brut constitue notamment d'astragali radix | |
JP4686173B2 (ja) | ポリフェノールおよび/またはビタミンcを含有するアセロラ処理物 | |
JP2012051940A (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
KR20100042414A (ko) | 오매 추출물 또는 이의 분획물을 유효성분으로 함유하는 혈행개선 조성물 | |
US6329000B1 (en) | Extract of pine needle and the use thereof | |
KR101729003B1 (ko) | 황칠 추출물 또는 황칠액 발효대사체를 포함하는 통풍 예방 또는 치료용 조성물 | |
KR100494482B1 (ko) | 간세포 보호 효과를 갖는 황칠 추출물, 황칠 분획물 및이들을 함유한 약학 조성물 | |
KR20060130149A (ko) | 적색 포도나무 잎의 수성 추출물 및 혈액 순환 개선제를포함하는, 만성 정맥 부전증을 치료하기 위한 조성물 | |
KR100504966B1 (ko) | 진세노사이드 Rg3 및 Rh2를 함유함을 특징으로 하는 항고혈압 조성물 | |
KR102538751B1 (ko) | 포도잎 추출물을 유효성분으로 함유하는 발기부전 치료용 약학적 조성물 및 식품 조성물 | |
KR100506950B1 (ko) | 진세노사이드를 함유함을 특징으로 하는 면역증강효과에 대한 조성물 | |
KR102279105B1 (ko) | 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물 | |
KR20040080640A (ko) | 항통풍활성을 갖는 개다래 추출물을 함유하는 약학조성물 | |
JPH09241157A (ja) | リソスペルメートb含有肝臓保護作用医薬組成物 | |
KR100940133B1 (ko) | 지각 추출물을 함유하는 당뇨병 치료 조성물 및 이를유효성분으로 하는 건강보조식품 | |
KR100485936B1 (ko) | 진세노사이드 Rh2 및 Rg3 항암 조성물 | |
CN1686242A (zh) | 具有高血脂及心脑血管疾病疗效的组合物 | |
KR100678562B1 (ko) | 혈압 강하제로서의 대나무 추출물의 용도 | |
KR102069125B1 (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
KR20190017394A (ko) | 해마 추출물을 포함하는 간섬유화 치료 또는 개선용 조성물 | |
JP2002212085A (ja) | 尿酸値低下剤 | |
WO2018048274A1 (ko) | 간손상 예방, 개선 또는 치료용 조성물 | |
KR100213667B1 (ko) | 항당뇨 효과를 가지는 조성물 | |
CN112999233A (zh) | 一类来源于赤芍的单萜苷类化合物及其制法和应用 | |
KR101319552B1 (ko) | 조각자 추출물을 유효성분으로 함유하는 당뇨병 및 당뇨병 합병증의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120628 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20130722 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141022 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150824 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170706 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180712 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20190718 Year of fee payment: 15 |